579
579
规格:
货期:
编号:TS212821
品牌:Testobio
| 产品名称： | 579 |
|---|---|
| 商品货号： | TS212821 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The antibody reacts with EGF receptors, blocks the binding of EGF to the receptor, and inhibits the growth of A-431 tumor cells in vitro. The antibody binds to a single class of receptor sites on A-431, HeLa and human fibroblasts. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Animals were immunized with partially purified EGF receptors from A-431 cells. Spleen cells were fused with P3X63Ag8.653 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against epidermal growth factor (EGF) receptor |
| Cellular Products： | immunoglobulin; monoclonal antibody; against epidermal growth factor (EGF) receptor |
| Tumorigenic： | Yes |
| Effects： | Yes, forms ascites in pristane primed BALB/cJ mice |
| Comments： | Animals were immunized with partially purified EGF receptors from A-431 cells. Spleen cells were fused with P3X63Ag8.653 myeloma cells. The antibody reacts with EGF receptors, blocks the binding of EGF to the receptor, and inhibits the growth of A-431 tumor cells in vitro. The antibody binds to a single class of receptor sites on A-431, HeLa and human fibroblasts. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: horse serum to a final concentration of 10%.
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Isotype： | IgG |
| Name of Depositor： | Regents of the University of California |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| U.S. Patent Number： | |
| References： | Mendelsohn J, et al. Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor. US Patent 4,943,533 dated Jul 24 1990 Sato JD, et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1: 511-529, 1983. PubMed: 6094961 |
首页 >
产品中心
>
微生物培养
>
菌株
>
null
>
579
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | 579 |
|---|---|
| 商品货号： | TS212821 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The antibody reacts with EGF receptors, blocks the binding of EGF to the receptor, and inhibits the growth of A-431 tumor cells in vitro. The antibody binds to a single class of receptor sites on A-431, HeLa and human fibroblasts. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Animals were immunized with partially purified EGF receptors from A-431 cells. Spleen cells were fused with P3X63Ag8.653 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against epidermal growth factor (EGF) receptor |
| Cellular Products： | immunoglobulin; monoclonal antibody; against epidermal growth factor (EGF) receptor |
| Tumorigenic： | Yes |
| Effects： | Yes, forms ascites in pristane primed BALB/cJ mice |
| Comments： | Animals were immunized with partially purified EGF receptors from A-431 cells. Spleen cells were fused with P3X63Ag8.653 myeloma cells. The antibody reacts with EGF receptors, blocks the binding of EGF to the receptor, and inhibits the growth of A-431 tumor cells in vitro. The antibody binds to a single class of receptor sites on A-431, HeLa and human fibroblasts. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: horse serum to a final concentration of 10%.
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Isotype： | IgG |
| Name of Depositor： | Regents of the University of California |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| U.S. Patent Number： | |
| References： | Mendelsohn J, et al. Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor. US Patent 4,943,533 dated Jul 24 1990 Sato JD, et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1: 511-529, 1983. PubMed: 6094961 |
